The verdict
Our read at a glance.
Whether early trials of DMT and 5-MeO-DMT in depression support their use as treatments, given the early stage and the intensity of the experience.
- The signal
- Early-phase trials are testing DMT and 5-MeO-DMT for depression, with companies reporting preliminary signals from small studies, and there is observational research on ayahuasca. The evidence is early, the studies are small, and there are no approvals. Effects are intense and short-lived.
- The unknown
- Whether benefits seen in small early trials hold up in larger controlled studies, how to deliver these intense experiences safely, and how much the drug versus the setting and support matters.
- Our read
- Fast-acting psychedelics in early, supervised testing for depression, not proven or approved treatments. The early signals are interesting, but the studies are small and the experiences intense, so these should be read as early investigational research, not ready therapies.
The mechanism
How it works.
DMT and 5-MeO-DMT are short-acting psychedelic tryptamines (DMT is the active component of ayahuasca, 5-MeO-DMT is found in some toad venom). Both act mainly as agonists at the brain's serotonin 2A (5-HT2A) receptors, the same target as psilocybin and LSD, which rapidly alters perception and thought. The leading idea is that this surge of 5-HT2A activity briefly increases neural plasticity, and paired with psychological support that window is being tested for fast relief of depression, though the human trials are small and early.
Safety & regulatory boundary
The consequential part.
DMT and 5-MeO-DMT are controlled substances and are not approved treatments. The studied model uses them only in supervised clinical settings because the experiences are intense and can carry cardiovascular and psychological risks. Early trial signals do not support recreational, ceremonial, or unsupervised use, which is different from the studied treatment.
What's next
What we're watching.
Larger controlled trials in depression, safety and delivery data, and regulatory progress.
Context
Why this is discussed.
DMT and 5-MeO-DMT are drawing interest as fast-acting psychedelics for depression, with the appeal of short, in-clinic sessions, and through the popularity of ayahuasca and toad-derived 5-MeO-DMT.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-05
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-08-01
ClinicalTrials.gov · PHASE2 · RECRUITING · 2023-02-10
ClinicalTrials.gov · RECRUITING · 2024-10-28
ClinicalTrials.gov · RECRUITING · 2024-12-12
ClinicalTrials.gov · RECRUITING · 2022-05-10
ClinicalTrials.gov · PHASE1/PHASE2 · ACTIVE_NOT_RECRUITING · 2023-12-01
ClinicalTrials.gov · NA · RECRUITING · 2025-08-05
Indexed literature (PubMed)12
Yao Y et al. · Psychiatry Res · 2024
Kalfas M et al. · Expert Opin Pharmacother · 2023
Ko K et al. · J Affect Disord · 2023
Kamal S et al. · Psychiatr Clin North Am · 2023
Warren AL et al. · Nature · 2024
Reckweg JT et al. · J Neurochem · 2022
Davis AK et al. · Am J Drug Alcohol Abuse · 2019
James E et al. · Hum Psychopharmacol · 2022
Ermakova AO et al. · J Psychopharmacol · 2022
Palhano-Fontes F et al. · Psychol Med · 2019
Friedberg LM et al. · Metab Eng · 2023
Keep reading